South Korean Biotech News - Latest Updates & Headlines
Celltrion gets interchangeability approval for biosimilar of Humira in US
Seoul, April 14: Celltrion, a major South Korean biopharmaceutical firm, on Monday said it has obtained an interchangeability approval for its biosimilar drug for autoimmune disease treatment in the United States.
Celltrion targets $3.46 bn in sales this year on biosimilars
Seoul, March 18: Celltrion, a major South Korean biopharmaceutical firm, on Tuesday said it aims to achieve 5 trillion won ($3.46 billion) in sales this year, helped by an expanded biosimilar lineup.